OTC Naproxen Labeling: US FDA Advisory Panel Finds Imprecise Direction In PRECISION
Executive Summary
Safety study of celecoxib vs. ibuprofen and naproxen spurs advisory committees to recommend adding aspirin-interaction warning on OTC naproxen labels, but many panelist made clear that PRECISION results had not swayed their thinking on celecoxib CV safety or on the OTC ingredients' interaction with aspirin.
You may also be interested in...
No GRASE For Ibuprofen, No Future In OTC Internal Analgesic Monograph
Nonprescription products containing ibuprofen can now only be marketed in the US through NDAs. No companies took advantage of a proposed ibuprofen addition to the the internal analgesic, antipyretic and antirheumatic OTC monograph, issued in 2002.
No GRASE For Ibuprofen, No Future In OTC Internal Analgesic Monograph
Nonprescription products containing ibuprofen can now only be marketed in the US through NDAs. No companies took advantage of a proposed ibuprofen addition to the the internal analgesic, antipyretic and antirheumatic OTC monograph, issued in 2002.
Celebrex Study Is Feel Good Story For Pfizer, But Are There Any Real Benefits?
Companies with pipeline pain products may see a smoother path through FDA, but Celebrex already has generic competition in the US, limiting the benefits even if it could get the black box removed from labeling and Pfizer also recently settled a lawsuit for $468 million related to the drug's safety.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: